Skip to main content
    C

    Cognition Therapeutics Inc (CGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.64
    -0.04 (-6.03%)

    Market Cap: $64.65M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Cognition Therapeutics Inc (CGTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Cognition Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$23.49M, operating cash flow was -$24.59M and free cash flow was -$24.59M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.14M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $47.80M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$15.21M+40.1%100.0%-188.0%-77.0%
    Dec 2020$10.86MN/A100.0%-160.4%-72.2%
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$0$0$0$15.21M$10.86M$0
    Cost of revenue$0$0$0$0$0$0$81.00K
    Gross profit$0$0$0$0$15.21M$10.86M-$81.00K
    Research and development$37.19M$41.68M$37.20M$30.32M$18.57M$12.89M$14.38M
    Operating income-$47.80M-$53.97M-$50.72M-$43.55M-$28.60M-$17.41M-$17.83M
    Net income-$23.49M-$33.97M-$25.79M-$21.40M-$11.72M-$7.84M-$6.95M
    EBITDA-$23.26M-$33.70M-$25.54M-$21.16M-$26.00M-$15.88M-$3.74M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$250.00K$0$0$0$372.00K
    Gross profit$0$0$0-$61.00K$0$0$0-$71.00K$0$0$0$306.00K
    Operating income-$7.38M-$7.74M-$8.82M-$13.67M-$6.38M-$13.98M-$13.78M-$10.72M-$14.46M-$14.68M-$14.10M-$15.19M
    Net income-$4.14M-$3.94M-$4.58M-$3.34M-$4.93M-$6.74M-$8.48M-$7.84M-$9.94M-$7.04M-$9.15M-$8.14M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $443.00K by $36.37M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$48.39M$30.23M$35.16M$50.42M$59.14M$7.12M$7.46M
    Current assets$47.99M$29.55M$34.22M$47.65M$58.99M$6.91M$7.16M
    Cash and equivalents$36.81M$25.01M$29.92M$41.56M$54.72M$5.19M$2.89M
    Total liabilities$14.12M$11.48M$10.69M$10.18M$7.86M$19.93M$65.88M
    Short-term debt$443.00K$472.00K$718.00K$783.00K$753.00KN/A$4.00K
    Long-term debtN/AN/AN/AN/AN/A$12.85M$6.90M
    Shareholder equity$34.27M$18.75M$24.47M$40.25M$51.27M-$68.18M-$58.42M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$34.80M$38.90M$36.14M$48.39M$43.40M$19.62M$23.50M$30.23M$27.58M$34.37M$38.85M$35.16M
    Total liabilities$5.53M$5.87M$6.23M$14.12M$6.87M$12.59M$11.23M$11.48M$13.10M$11.36M$9.99M$10.69M
    Cash and equivalents$30.76M$34.01M$31.13M$37.00M$39.33M$10.74M$16.43M$25.01M$22.01M$28.53M$34.67M$29.92M
    Shareholder equity$29.28M$33.02M$29.91M$34.27M$36.53M$7.03M$12.27M$18.75M$14.48M$23.01M$28.86M$24.47M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$24.59M-$28.47M-$16.02M-$18.53M-$3.63M-$3.43M-$3.10M
    Capital expenditures$0$4.00K$147.00K$171.00K$27.00K$10.00K$144.00K
    Free cash flow-$24.59M-$28.48M-$16.16M-$18.70M-$3.66M-$3.44M-$3.24M
    Investing cash flow$9.00K-$4.00K-$147.00K-$171.00K-$27.00K-$10.00K-$144.00K
    Financing cash flow$36.57M$23.57M$4.52M$5.55M$53.20M$5.76M$2.79M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.26M-$3.05M-$5.54M-$3.44M-$5.65M-$5.62M-$9.88M-$8.38M-$6.85M-$6.00M-$7.24M-$5.46M
    Capital expendituresN/AN/A$0$0$0$0$0$1.00K$3.00K$3.00K$0$30.00K
    Free cash flowN/AN/A-$5.54M-$3.44M-$5.65M-$5.62M-$9.88M-$8.38M-$6.85M-$6.00M-$7.24M-$5.49M
    Last 12 quarters

    Frequently Asked Questions About CGTX

    What is Cognition Therapeutics' annual revenue?

    Cognition Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Cognition Therapeutics profitable?

    No. Cognition Therapeutics reported net income of -$23.49M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CGTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.59M minus capital expenditures of $0 produced free cash flow of -$24.59M.

    How much debt does Cognition Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $443.00K and cash and equivalents of $36.81M.